+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Skin Cancer Drugs Market Research Reports

Refractory Metastatic Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Refractory Metastatic Melanoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
Cutaneous Squamous Cell Carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Cutaneous Squamous Cell Carcinoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 120 Pages
  • Global
From
Metastatic Merkel Cell Carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Metastatic Merkel Cell Carcinoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 90 Pages
  • Global
From
Gorlin-syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Gorlin-syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Uveal Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Uveal Melanoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 90 Pages
  • Global
From
Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Melanoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 180 Pages
  • Global
From
Unresectable Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Unresectable Melanoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Esophageal Squamous Cell Carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Esophageal Squamous Cell Carcinoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 150 Pages
  • Global
From
Head and Neck Squamous Cell Carcinoma (HNSCC) - Pipeline Insight, 2024 - Product Thumbnail Image

Head and Neck Squamous Cell Carcinoma (HNSCC) - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Metastatic Cutaneous Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Metastatic Cutaneous Melanoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Nonmelanoma Skin Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Nonmelanoma Skin Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Nevoid basal cell carcinoma syndrome (NBCCS) - Pipeline Insight, 2024 - Product Thumbnail Image

Nevoid basal cell carcinoma syndrome (NBCCS) - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Metastatic Cutaneous Squamous Cell Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Metastatic Cutaneous Squamous Cell Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Advanced Merkel cell carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Advanced Merkel cell carcinoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 80 Pages
  • Global
From
KEYTRUDA Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

KEYTRUDA Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • April 2024
  • 30 Pages
  • Global
From
BRAF-Mutant Metastatic Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

BRAF-Mutant Metastatic Melanoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Basal Cell Neoplasms - Pipeline Insight, 2024 - Product Thumbnail Image

Basal Cell Neoplasms - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Malignant Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Malignant Melanoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Merkel Cell Carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Merkel Cell Carcinoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
Metastatic Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Metastatic Melanoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 250 Pages
  • Global
From
Loading Indicator

The Skin Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat skin cancer. These drugs are used to treat a variety of skin cancer types, including melanoma, basal cell carcinoma, and squamous cell carcinoma. The drugs are typically administered orally, intravenously, or topically. The market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Novartis, Pfizer, and Roche. These companies are constantly researching and developing new treatments to improve the efficacy of existing treatments and to develop new treatments for skin cancer. In addition to the major players, there are also many smaller companies that are developing treatments for skin cancer. These companies are often focused on developing treatments for rarer forms of skin cancer, such as Merkel cell carcinoma. Examples of these companies include Aduro Biotech, Arcutis Biotherapeutics, and OncoSec Medical. Show Less Read more